Entero Therapeutics Files 8-K/A Amendment
Ticker: GRDX · Form: 8-K/A · Filed: May 30, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K/A |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Entero Therapeutics filed an amendment to an old report, mostly housekeeping.
AI Summary
Entero Therapeutics, Inc. filed an amendment (8-K/A) on May 30, 2024, to its report originally dated March 13, 2024. This amendment pertains to financial statements and exhibits, with no specific new financial figures or material events detailed in the provided excerpt.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be relevant for investors tracking the company's disclosures.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material financial information or significant events.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- March 13, 2024 (date) — Earliest event reported date
- May 30, 2024 (date) — Filing date of the amendment
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 2) to a previous Form 8-K, specifically related to financial statements and exhibits.
What was the original report date for the filing being amended?
The earliest event reported date for the original filing was March 13, 2024.
When was this amendment filed with the SEC?
This amendment was filed as of May 30, 2024.
What are some of the former names of Entero Therapeutics, Inc.?
Former names include First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
What is the primary business of Entero Therapeutics, Inc. according to the filing?
The Standard Industrial Classification (SIC) code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 814 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-05-30 17:18:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO The Nasdaq Capital
Filing Documents
- tm2416013d1_8ka.htm (8-K/A) — 31KB
- tm2416013d1_ex99-3.htm (EX-99.3) — 54KB
- 0001104659-24-066738.txt ( ) — 263KB
- fwbi-20240313.xsd (EX-101.SCH) — 3KB
- fwbi-20240313_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240313_pre.xml (EX-101.PRE) — 22KB
- tm2416013d1_8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (b) Pro forma Financial Information The unaudited pro forma combined statements of operations as of March 31, 2024 that give effect to the Merger are attached hereto as Exhibit 99.3, and are incorporated herein by reference. (d) Exhibits Exhibit Number Description 23.1 Consent of Holthouse Carlin & Van Trigt LLP (incorporated by reference to Exhibit 23.1 to the Company's Current Report on Form 8-K/A filed with the SEC on May 8, 2024). 99.1 Audited financial statements of IMGX for the fiscal years ended December 31, 2023, 2022 and 2021 (incorporated by reference o Exhibit 99.1 to the Company's Current Report on Form 8-K/A filed with the SEC on May 8, 2024) . 99.2 Unaudited pro forma combined balance sheet of the Company and IMGX as of December 31, 2023 and unaudited pro forma combined statements of operations of the Company and IMGX for the year ended December 31, 2023 (incorporated by reference to Exhibit 99.3 to the Company's Current Report on Form 8-K/A filed with the SEC on May 8, 2024). 99.3* Unaudited pro forma combined statements of operations of the Company and IMGX for the three months ended March 31, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL). * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENTERO THERAPEUTICS, Inc. Date: May 30, 2024 By: /s/ Sarah Romano Sarah Romano Chief Financial Officer